 Bleomycin
"Bleomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
| Descriptor ID |
D001761
|
| MeSH Number(s) |
D09.400.420.110 D12.644.233.110
|
| Concept/Terms |
BLEO-cell- BLEO-cell
- BLEO cell
- BLEOcell
- cell pharm Brand of Bleomycin Sulfate
Bleolem- Bleolem
- Lemery Brand of Bleomycin Sulfate
Bleomicina- Bleomicina
- Almirall Brand of Bleomycin Sulfate
Bleomycinum Mack- Bleomycinum Mack
- Mack, Bleomycinum
- Mack Brand of Bleomycin Sulfate
Bléomycine Bellon- Bléomycine Bellon
- Bellon, Bléomycine
- Bellon Brand of Bleomycin Sulfate
Blenoxane- Blenoxane
- Bristol-Myers Squibb Brand of Bleomycin Sulfate
- Bristol Myers Squibb Brand of Bleomycin Sulfate
- Blanoxan
|
Below are MeSH descriptors whose meaning is more general than "Bleomycin".
Below are MeSH descriptors whose meaning is more specific than "Bleomycin".
This graph shows the total number of publications written about "Bleomycin" by people in this website by year, and whether "Bleomycin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 2 | 0 | 2 | | 1982 | 0 | 4 | 4 | | 1984 | 0 | 2 | 2 | | 1985 | 0 | 3 | 3 | | 1987 | 1 | 1 | 2 | | 1988 | 1 | 2 | 3 | | 1989 | 0 | 2 | 2 | | 1990 | 0 | 3 | 3 | | 1992 | 0 | 2 | 2 | | 1993 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 1 | 2 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 0 | 2 | 2 | | 2007 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 3 | 3 | | 2013 | 1 | 3 | 4 | | 2014 | 0 | 1 | 1 | | 2015 | 3 | 1 | 4 | | 2016 | 1 | 3 | 4 | | 2017 | 1 | 3 | 4 | | 2018 | 2 | 1 | 3 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Bleomycin" by people in Profiles.
-
Duan FF, Barron G, Meliton A, Mutlu GM, Dulin NO, Schuger L. P311 Promotes Lung Fibrosis via Stimulation of Transforming Growth Factor-ß1, -ß2, and -ß3 Translation. Am J Respir Cell Mol Biol. 2019 02; 60(2):221-231.
-
Koo HY, El-Baz LM, House S, Cilvik SN, Dorry SJ, Shoukry NM, Salem ML, Hafez HS, Dulin NO, Ornitz DM, Guzy RD. Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation. J Pathol. 2018 09; 246(1):54-66.
-
Hamanaka RB, Nigdelioglu R, Meliton AY, Tian Y, Witt LJ, O'Leary E, Sun KA, Woods PS, Wu D, Ansbro B, Ard S, Rohde JM, Dulin NO, Guzy RD, Mutlu GM. Inhibition of Phosphoglycerate Dehydrogenase Attenuates Bleomycin-induced Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2018 05; 58(5):585-593.
-
Pinnix CC, Wirth A, Milgrom SA, Andraos TY, Aristophanous M, Pham M, Hancock D, Ludmir EB, Gunther JR, Fanale MA, Oki Y, Nastoupil L, Chuang HH, Mikhaeel NG, Dabaja BS. Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leuk Lymphoma. 2018 11; 59(11):2650-2659.
-
Knipe RS, Probst CK, Lagares D, Franklin A, Spinney JJ, Brazee PL, Grasberger P, Zhang L, Black KE, Sakai N, Shea BS, Liao JK, Medoff BD, Tager AM. The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2018 04; 58(4):471-481.
-
Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer. 2018 01 01; 124(1):136-144.
-
Hrusch CL, Manns ST, Bryazka D, Casaos J, Bonham CA, Jaffery MR, Blaine KM, Mills KAM, Verhoef PA, Adegunsoye AO, Williams JW, Tjota MY, Moore TV, Strek ME, Noth I, Sperling AI. ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol. 2018 01; 11(1):61-70.
-
Guzy RD, Li L, Smith C, Dorry SJ, Koo HY, Chen L, Ornitz DM. Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling. J Biol Chem. 2017 06 23; 292(25):10364-10378.
-
Jablonski RP, Kim SJ, Cheresh P, Williams DB, Morales-Nebreda L, Cheng Y, Yeldandi A, Bhorade S, Pardo A, Selman M, Ridge K, Gius D, Budinger GRS, Kamp DW. SIRT3 deficiency promotes lung fibrosis by augmenting alveolar epithelial cell mitochondrial DNA damage and apoptosis. FASEB J. 2017 06; 31(6):2520-2532.
-
Kim SJ, Cheresh P, Jablonski RP, Morales-Nebreda L, Cheng Y, Hogan E, Yeldandi A, Chi M, Piseaux R, Ridge K, Michael Hart C, Chandel N, Scott Budinger GR, Kamp DW. Mitochondrial catalase overexpressed transgenic mice are protected against lung fibrosis in part via preventing alveolar epithelial cell mitochondrial DNA damage. Free Radic Biol Med. 2016 12; 101:482-490.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|